ArticleCancer cell2017
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Invasive pulmonary aspergillosis in the ICU: the corticosteroid link.Pneumonia (Nathan Qld.) · 2026Review
- Differential Effects of Zanubrutinib and Ibrutinib on Neutrophil Antifungal Functions: Insights from Live-Cell Imaging.Journal of innate immunity · 2026Article
- Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma.Leukemia · 2025Article
- Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity.Journal of the American Heart Association · 2024Article
- Liposomal amphotericin B-the present.The Journal of antimicrobial chemotherapy · 2022Article
- Article
- The genomic and transcriptional landscape of primary central nervous system lymphoma.Nature communications · 2022Article
- Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma.Blood and lymphatic cancer : targets and therapy · 2022Article
- Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.Cancer medicine · 2021Article
- Article
- Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.Medical mycology · 2021Article
- Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review.Journal of blood medicine · 2021Article
- Invasive Aspergillosis in Patients Treated With Ibrutinib.HemaSphere · 2020Article
- Ibrutinib induces multiple functional defects in the neutrophil response againstHaematologica · 2020Article
- Prophylaxis of mould infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Review
- Review
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.Haematologica · 2018Article
- Article
- First-line ibrutinib for Bing-Neel syndrome.BMJ case reports · 2018Article
- Biology of CNS lymphoma and the potential of novel agents.Hematology. American Society of Hematology. Education Program · 2017Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients with primary central nervous system lymphoma but was associated with significant toxicity, including pulmonary and cerebral aspergillosis infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.